M-M-R II vaccine

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

VaccineVaccination

35 competitors in Vaccine

#DrugCompanyPhaseTrials

1

Rotarix ™

GSK

Phase 3

52

Havrix

GSK

Phase 3

13

Varivax

GSK

Phase 3

34

Rotateq

Merck & Co.

Phase 3

35

Vaxelis Vaccine

Sanofi

Phase 3

26

Priorix

GSK

Phase 3

17

Trumenba

Pfizer

Phase 3

18

Bayer Aspirin

Bayer

Phase 1

19

M-M-R II vaccine

Sanofi

Phase 3

210

Varivax Vaccine

Sanofi

Phase 3

1Show 15 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Vaccine2 trials

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06736041·1,714 enrolled

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting·Sanofi·Phase 3·NCT06824194·2,320 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06824181·580 enrolled

Details

Drug Info

Related News